tert-butyl 4-(3-methoxy-4-(methoxycarbonyl)phenyl)piperazine-1-carboxylate | 1154414-87-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-(3-methoxy-4-(methoxycarbonyl)phenyl)piperazine-1-carboxylate
• 英文别名: Tert-butyl 4-(3-methoxy-4-methoxycarbonylphenyl)piperazine-1-carboxylate
• CAS: 1154414-87-5
• 化学式: C₁₈H₂₆N₂O₅
• 分子量: 350.415
• InChiKey: NCFPUJQPVOAEEZ-UHFFFAOYSA-N

物化性质

• 沸点：
  485.5±45.0 °C(Predicted)
• 密度：
  1.160±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  68.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(3-methoxy-4-(methoxycarbonyl)phenyl)piperazine-1-carboxylate 在 sodium hydroxide 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 17.0h， 生成 C₁₇H₂₄N₂O₅
  参考文献：
  名称：

  Base-Mediated Oxidative Degradation of Secondary Amides Derived from p-Amino Phenol to Primary Amides in Drug Molecules

  摘要：

  One of the most common functional groups encountered in drug molecules is the amide, and the most common degradation pathway for amides is base-mediated hydrolysis to its constituent amine and carboxylic acid. Herein, we report for the first time, a base-mediated oxidative degradation pathway of secondary amides to primary amides. This transformation also represents a novel synthetic methodology, reported for the first time in this work, in transforming secondary amides to primary amides without using any oxidative reagents. The introduction of this mechanism into the pharmaceutical literature is important given that the mechanism and required reactants are present to carry out the chemistry in dosage forms. (C) 2020 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.xphs.2020.07.028
• 作为产物：
  描述：

  4-氟水杨酸 在 potassium carbonate 作用下， 以 二甲基亚砜 、 丙酮 为溶剂， 反应 38.66h， 生成 tert-butyl 4-(3-methoxy-4-(methoxycarbonyl)phenyl)piperazine-1-carboxylate
  参考文献：
  名称：

  [EN] PHARMACEUTICAL COMPOUNDS
  [FR] COMPOSÉS PHARMACEUTIQUES

  摘要：

  这项发明涉及抑制或调节Chk-1激酶活性的化合物。还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。

  公开号：

  WO2015120390A1

文献信息

• Pharmaceutical compounds
  申请人：CASCADIAN THERAPEUTICS, INC.

  公开号：US10010547B2

  公开（公告）日：2018-07-03

  This invention relates to compounds that inhibit or modulate the activity of Chk-1 kinase. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.

  本发明涉及抑制或调节 Chk-1 激酶活性的化合物。本发明还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。
• Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
  申请人：ARVINAS OPERATIONS, INC.

  公开号：US11173211B2

  公开（公告）日：2021-11-16

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，它们可用作快速加速纤维肉瘤（RAF，如c-RAF、A-RAF和/或B-RAF；靶蛋白）的调节剂。特别是，本公开内容涉及双功能化合物，其一端含有与相应 E3 泛素连接酶结合的 Von Hippel-Lindau、cereblon、抑制细胞凋亡蛋白或小鼠双敏同源物 2 配体，另一端含有与靶蛋白 RAF 结合的分子，从而将靶蛋白置于泛素连接酶附近，以实现对靶蛋白的降解（和抑制）。本公开物具有与降解/抑制靶蛋白相关的广泛药理活性。本公开的化合物和组合物可以治疗或预防由于靶蛋白的聚集或积聚或靶蛋白的组成性激活而导致的疾病或失调。
• [EN] EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS<br/>[FR] INHIBITEURS DU TRANSPORTEUR ÉQUILIBRANT DES NUCLÉOSIDES ENT1
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009062990A3

  公开（公告）日：2009-09-24
• Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology
  作者：Liqi He、Meng Yao Zhang、Matthew Cox、Qian Zhang、Andrew F. Donnell、Yong Zhang、Christine Tarby、Patrice Gill、Murugaiah A. M. Subbaiah、Thangeswaran Ramar、Maheswara Reddy、Vijaya Puttapaka、Yi-Xin Li、Prasanna Sivaprakasam、David Critton、Dawn Mulligan、Chunshan Xie、Radha Ramakrishnan、Jignesh Nagar、Shailesh Dudhgaonkar、Anwar Murtaza、Martins S. Oderinde、Gary L. Schieven、Arvind Mathur、Ashvinikumar V. Gavai、Gregory Vite、Sanjeev Gangwar、Yam B. Poudel

  DOI：10.1021/acsmedchemlett.3c00456

  日期：2024.2.8
• PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS
  申请人：Sentinel Oncology Limited

  公开号：EP3104860B1

  公开（公告）日：2020-12-30